NCT07075510View on ClinicalTrials.gov

Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2030

Study Completion Date

October 1, 2032

Conditions

Plasma Cell Disorder

Interventions

DRUG

Daratumumab Injection

Daratumumab Administration in the Anterior Upper Thigh versus the Abdomen

Sponsors

Collaborators (1)

Johnson & Johnson

All Listed Sponsors

collaborator

Johnson & Johnson

INDUSTRY

lead

University of Maryland, Baltimore

OTHER